Roche Says Actemra-Remdesivir Trial Fails to Cut Hospital Stays Roche Says Actemra-Remdesivir Trial Fails to Cut Hospital Stays
Swiss drugmaker Roche said on Thursday adding its drug Actemra to Gilead Sciences ' Veklury medication, also called remdesivir, did not reduce hospital stays for patients with severe COVID-19 pneumonia.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - March 12, 2021 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Combo of Genentech, Gilead drugs fails Covid trial
The study is one of three late-stage clinical trials that Genentech has undertaken to assess the use of the rheumatoid arthritis drug Actemra in Covid patients with pneumonia. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 11, 2021 Category: Biotechnology Authors: Ron Leuty Source Type: news

Combo of Genentech, Gilead drugs fails Covid trial
The study is one of three late-stage clinical trials that Genentech has undertaken to assess the use of the rheumatoid arthritis drug Actemra in Covid patients with pneumonia. (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - March 11, 2021 Category: American Health Authors: Ron Leuty Source Type: news

Tocilizumab Use Not Supported for Moderate-to-Severe COVID-19
THURSDAY, March 11, 2021 -- Tocilizumab is not associated with progression of COVID-19 among adults admitted to hospital with moderate-to-severe COVID-19, according to a study published online March 4 in The Lancet Respiratory Medicine. Arvinder S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra ®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc. (Source: Roche Media News)
Source: Roche Media News - March 11, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on the phase III REMDACTA trial of Actemra/RoActemra plus Veklury in patients with severe COVID-19 pneumonia
Basel, 11 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the global phase III randomised, double-blind, multicentre REMDACTA study of Actemra ®/RoActemra® (tocilizumab) plus Veklury® (remdesivir), versus placebo plus Veklury, did not meet its primary endpoint. This was measured by improved time to hospital discharge up to day 28 in patients with severe COVID-19 pneumonia receiving standard of care. No new safety signals were identified for Actemra/RoActemra in the REMDACTA trial. The study was conducted in collaboration with Gilead Sciences, Inc. (Source: Roche Investor Update)
Source: Roche Investor Update - March 11, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab Scores FDA Approval for SSc-ILD Tocilizumab Scores FDA Approval for SSc-ILD
Tocilizumab is the first biologic to be approved by the agency for adults with systemic sclerosis –associated interstitial lung disease, a rare, potentially life-threatening condition.FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 8, 2021 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India
Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India — one of the world ’ s most ethnically diverse countries. (Source: University of Bristol news)
Source: University of Bristol news - March 8, 2021 Category: Universities & Medical Training Tags: Health, International, Publications, Research; Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news

Tocilizumab cuts mortality risk in severely ill COVID-19 patients finds new trial conducted in India
(University of Bristol) Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India -- one of the world's most ethnically diverse countries. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 8, 2021 Category: International Medicine & Public Health Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no cure. ...
Source: Roche Media News - March 5, 2021 Category: Pharmaceuticals Source Type: news

Roche ’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for the treatment of the disease. Systemic sclerosis (SSc), also known as scleroderma, is an often devastating autoimmune disease that worsens over time and has no cure. ...
Source: Roche Investor Update - March 5, 2021 Category: Pharmaceuticals Source Type: news

Does an Arthritis Drug Help Patients Battling Severe COVID? It Depends on the Study
WEDNESDAY, March 3, 2021 -- Two new studies suggest that the jury is still out on whether the arthritis drug tocilizumab helps those with severe COVID-19. Both reports were published recently in the New England Journal of Medicine. The first, from... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 3, 2021 Category: General Medicine Source Type: news

​IL - 6 Receptor Antagonists Benefit Critically Ill With COVID - 19 ​
Improved outcomes, including more organ support - free days, reduced mortality, seen with tocilizumab, sarilumab (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 2, 2021 Category: Respiratory Medicine Tags: Infections, Pharmacy, Pulmonology, Critical Care, Journal, Source Type: news

​IL-6 Receptor Antagonists Benefit Critically Ill With COVID-19​
TUESDAY, March 2, 2021 -- Treatment with interleukin-6 receptor antagonists tocilizumab and sarilumab improves outcomes among critically ill patients with COVID-19 receiving organ support in the intensive care unit (ICU), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 2, 2021 Category: Pharmaceuticals Source Type: news

Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia, New England Journal of Medicine
This placebo-controlled Phase III study of tocilizumab in patients hospitalised with severe Covid-19 pneumonia found no improvement in clinical status (primary endpoint; between-group difference -1.0; 95% CI -2.5 to 0; p=0.31) or mortality (19.7% v 19.4%; p=0.94) at day 28. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - March 1, 2021 Category: Consumer Health News Source Type: news